TME Pharma N.V.

Research TME Pharma N.V. (ALTME) on Bullrun: market cap EUR 6.62M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerALTME
• ExchangePA
• CountryGermany
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 6.62M
• Financial periodFY2024
• Net income-EUR 5.72M
• Free cash flow-EUR 4.65M

Valuation Snapshot

latest market cap is EUR 6.62M.

About TME Pharma N.V.

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma.

Frequently asked questions

What is TME Pharma N.V.'s market cap?

TME Pharma N.V.'s market capitalization is EUR 6.62M.

What does TME Pharma N.V. do?

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany.